Location of Repository

Alzheimer's disease -related genes and pathways special emphasis on seladin-1, [delta]opioid receptor 1 and BACE1

By Timo Sarajärvi
Publisher: University of Eastern Finland
OAI identifier: oai:epublications.uef.fi:3100

Suggested articles



  1. (2009). (11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients",
  2. (2006). 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease",
  3. (2008). 3betaHydroxysteroid-delta24 reductase is a hydrogen peroxide scavenger, protecting cells from oxidative stress-induced apoptosis",
  4. (2007). A beta oligomers - a decade of discovery",
  5. (2010). A GPCR/secretase complex regulates beta- and gamma-secretase specificity for Abeta production and contributes to AD pathogenesis",
  6. (1982). A new clinical scale for the staging of dementia", The British journal of psychiatry : the journal of mental science,
  7. (1985). A new method of preparing gold probes for multiplelabeling cytochemistry",
  8. (2007). A new multipoint method for genome-wide association studies by imputation of genotypes",
  9. (1984). A new rating scale for Alzheimer's disease",
  10. (2005). A nine-transmembrane domain topology for presenilin 1",
  11. (2001). A novel gamma -secretase assay based on detection106 of the putative C-terminal fragment-gamma of amyloid beta protein precursor",
  12. (1992). A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid",
  13. (2008). Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks",
  14. (2008). Abeta-degrading enzymes in Alzheimer's disease",
  15. (1998). Abnormalities of neural circuitry in Alzheimer's disease: hippocampus and cortical cholinergic innervation",
  16. (2006). Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation",
  17. (1993). Activation of protein kinase C inhibits cellular production of the amyloid beta-protein",
  18. (2003). ADAMs family members as amyloid precursor protein alpha-secretases",
  19. (2011). ADP ribosylation factor 6 (ARF6) controls amyloid precursor protein (APP) processing by mediating the endosomal sorting of BACE1",
  20. (2010). Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy",
  21. (1984). Aging, Alzheimer's disease, and the cholinergic system of the basal forebrain",
  22. (2007). Alkalizing drugs induce accumulation of amyloid precursor protein by-products in luminal vesicles of multivesicular bodies",
  23. (1998). Alpha-2 macroglobulin is genetically associated with Alzheimer disease",
  24. (2006). Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment",
  25. (2009). Alzheimer disease Abeta production in the absence of S-palmitoylation-dependent targeting of BACE1 to lipid rafts",
  26. (2003). Alzheimer disease in the US population: prevalence estimates using the 2000 census",
  27. (2004). Alzheimer disease: operating characteristics of PET--a meta-analysis",
  28. (2001). Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits",
  29. (2001). Alzheimer's disease and Abeta toxicity: from top to bottom",
  30. (1982). Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain",
  31. (2002). Alzheimer's disease is a synaptic failure", Science
  32. (2003). Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis",
  33. (1983). Alzheimer's disease: a disorder of cortical cholinergic innervation",
  34. (2005). Alzheimer's disease: Abeta, tau and synaptic dysfunction", Trends in molecular medicine,
  35. (1997). Alzheimer's disease: genotypes, phenotypes, and treatments",
  36. (1984). Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein", Biochemical and biophysical research communications,
  37. (2004). Alzheimer's disease: one disorder, too many genes?",
  38. (2011). Alzheimer's disease",
  39. (2004). Alzheimer's disease", The New England journal of medicine,
  40. (2009). Alzheimer's mechanisms in ischemic brain degeneration", Anatomical record
  41. (2001). Alzheimerin taudin kliininen kuva ja diagnoosi" in Muistihäiriöt ja dementia,
  42. (2005). Aminoterminally truncated Abeta peptide species are the main component of cotton wool plaques",
  43. (2010). Amyloid and tau proteins in cortical brain biopsy and Alzheimer's disease",
  44. (2004). Amyloid angiopathy-related vascular cognitive impairment", Stroke; a journal of cerebral circulation,
  45. (2003). Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways",
  46. (1987). Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus",
  47. (1995). Amyloid beta-protein ending at Thr43 is a minor component of some diffuse plaques in the Alzheimer's disease brain, but is not found in cerebrovascular amyloid",
  48. (2008). Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease", Trends in molecular medicine,
  49. (1991). Amyloid deposition as the central event in the aetiology of Alzheimer's disease", Trends in pharmacological sciences,
  50. (2009). Amyloid imaging in mild cognitive impairment subtypes",
  51. (2009). Amyloid precursor protein regulates Cav1.2 L-type calcium channel levels and function to influence GABAergic short-term plasticity",
  52. (2009). Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury",
  53. (2006). Amyloid precursor-like protein 1 influences endocytosis and proteolytic processing of the amyloid precursor protein",
  54. (1997). Amyloid, the presenilins and Alzheimer's disease", Trends in neurosciences,
  55. (2001). An alpha(2)-adrenergic antagonist, atipamezole, facilitates behavioral recovery after focal cerebral ischemia in rats",
  56. (2009). An association study between granulin gene polymorphisms and Alzheimer's disease in Finnish population",
  57. (1994). An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants",
  58. (2003). Antagonistic effects of beta-site amyloid precursor protein-cleaving enzymes 1 and 2 on beta-amyloid peptide production in cells",
  59. (2002). Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia",
  60. (2004). ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo",
  61. (2003). APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein", Neuropathology and applied neurobiology,
  62. (1997). ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative",
  63. (1995). Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in99 the cerebrospinal fluid in Finnish patients with Alzheimer's disease",
  64. (2003). Apolipoprotein E and beta-amyloid (1-42) regulation of glycogen synthase kinase-3beta",
  65. (2003). Apolipoprotein E and Reelin ligands modulate tau phosphorylation through an apolipoprotein E receptor/disabled1/glycogen synthase kinase-3beta cascade",
  66. (2006). Apolipoprotein E decreases tau kinases and phospho-tau levels in primary neurons",
  67. (1993). Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases",
  68. (2001). Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons",
  69. (1993). Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease",
  70. (2007). APP Biology, Processing and Function"
  71. (2003). APP processing and synaptic function",
  72. (2000). ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site", Molecular and cellular neurosciences,
  73. (2006). Assembly, trafficking and function of gammasecretase",
  74. (2009). Assessment of Alzheimer's disease case-control associations using family-based methods",
  75. (2004). Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes",
  76. (1998). Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17",
  77. (2003). Association of neprilysin polymorphism with cerebral amyloid angiopathy",
  78. (1997). Association of presenilin-1 polymorphism with cerebral amyloid angiopathy in the elderly", Stroke; a journal of cerebral circulation,
  79. (2005). Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus: revisited",
  80. (1999). BACE Maps to Chromosome 11 and a BACE Homolog, BACE2, Reside in the Obligate Down Syndrome Region of Chromosome 21",
  81. (2004). BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease",
  82. (2007). BACE1 regulates voltage-gated sodium channels and neuronal activity",
  83. (2004). BACE1: the beta-secretase enzyme in Alzheimer's disease",
  84. (2010). BACE2 plays a role in the insulin receptor trafficking in pancreatic ss-cells", American journal of physiology.Endocrinology and metabolism,
  85. (2005). Behavioral effects of photothrombotic ischemic cortical injury in aged rats treated with the sedativehypnotic GABAergic drug zopiclone",
  86. (1986). Bepridil block of cardiac calcium and sodium channels",
  87. (1985). Bepridil hydrochloride alters potential-dependent and receptor-operated calcium channels in vascular smooth muscle of rabbit aorta",
  88. (2007). Bepridil reverses atrial electrical remodeling and L-type calcium channel downregulation in a canine model of persistent atrial tachycardia",
  89. (1992). Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris",
  90. (1991). beta A4 amyloid protein deposition in brain after head trauma",
  91. (2005). beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase",
  92. (1988). Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues",
  93. (1995). beta-Amyloid-induced toxicity in rat hippocampal cells: in vitro evidence for the involvement of free radicals",
  94. (2002). Beta-secretase (BACE) as a drug target for Alzheimer's disease",
  95. (1999). Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE",
  96. (2001). beta-site APP cleaving enzyme mRNA expression in APP transgenic mice: anatomical overlap with transgene expression and static levels with aging", The American journal of pathology,
  97. (1993). betaAmyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms",
  98. (2008). Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology",
  99. (2007). Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice",
  100. (2010). Calcium signaling and amyloid toxicity in Alzheimer disease",
  101. (2003). Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice",
  102. (2007). Caspase-3 cleavage of GGA3 stabilizes BACE: implications for Alzheimer's disease",
  103. (2003). Causative and susceptibility genes for Alzheimer's disease: a review",
  104. (1998). Caveolae, plasma membrane microdomains for alpha-secretase-mediated processing of the amyloid precursor protein",
  105. (1990). Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer's disease",
  106. (2004). Cerebral amyloid angiopathy and gene polymorphisms",
  107. (1986). Cerebral amyloid angiopathy in Down's syndrome",
  108. (2009). Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain",
  109. (2003). Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?",
  110. (2001). Changes in the immune system in depression and dementia: causal or co-incidental effects?",
  111. (1987). Characterization and chromosomal localization of a cDNA encoding brain amyloid of Alzheimer's disease",
  112. (2000). Characterization of Alzheimer's beta -secretase protein BACE. A pepsin family member with unusual properties",
  113. (2001). Characterization of the glycosylation profiles of Alzheimer's beta -secretase protein Asp-2 expressed in a variety of cell lines",
  114. (2008). Characterization of tumour necrosis factor-alpha genetic variants and mRNA expression in patients with severe sepsis",
  115. (1990). Choline acetyltransferase activity and [3H]vesamicol binding in the temporal cortex of patients with Alzheimer's disease, Parkinson's disease, and rats with basal forebrain lesions",
  116. (2004). Clearance of Alzheimer's Abeta peptide: the many roads to perdition",
  117. (2000). Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier",
  118. (2004). Clearing amyloid through the blood-brain barrier",
  119. (1996). Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism",
  120. (2010). Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans",
  121. (1988). Clinical Dementia Rating (CDR)", Psychopharmacology bulletin,
  122. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease",
  123. (1995). Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease",
  124. (2010). Co-localization of the amyloid precursor protein and Notch intracellular domains in nuclear transcription factories",
  125. (2008). Coaccumulation of calcium and beta-amyloid in the thalamus after101 transient middle cerebral artery occlusion in rats",
  126. (2011). Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease",
  127. (2011). Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease",
  128. (2001). Compartmentalization of betasecretase (Asp2) into low-buoyant density, noncaveolar lipid rafts",
  129. (1994). Complete cerebral ischemia with short-term survival in rats induced by cardiac arrest. I. Extracellular accumulation of Alzheimer's beta-amyloid protein precursor in the brain",
  130. (1999). Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease",
  131. (2001). Constitutive shedding of the amyloid precursor protein ectodomain is up-regulated by tumour necrosis factor-alpha converting enzyme",
  132. (2006). Control of peripheral nerve myelination by the beta-secretase BACE1", Science
  133. (2009). Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study",
  134. (2000). Coordinated expression of beta-amyloid precursor protein and the putative beta-secretase BACE and alpha-secretase ADAM10 in mouse and human brain",
  135. (2008). Core candidate neurochemical and imaging biomarkers of Alzheimer's disease",
  136. (2001). Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline",
  137. (1978). Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia",
  138. (2003). CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study",
  139. (2009). CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment",
  140. (2006). CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease", Brain : a journal of neurology,
  141. (2007). CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study",
  142. (2004). Deciphering the molecular basis of memory failure in Alzheimer's disease",
  143. (2006). Deducing the transmembrane domain organization of presenilin-1 in gamma-secretase by cysteine disulfide crosslinking",
  144. (2001). Definitions and diagnostic criteria" in Clinical diagnosis and management of Alzheimer's
  145. (1985). Dementia"
  146. (2010). Dendritic function of tau mediates amyloidbeta toxicity in Alzheimer's disease mouse models",
  147. (2011). Depletion of CXCR2 inhibits gamma-secretase activity and amyloid-beta production in a murine model of Alzheimer's disease",
  148. (2007). Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity",
  149. (1993). Determination by PCR-RFLP of apo E genotype in a Japanese population",
  150. (2005). DHCR24 gene expression is upregulated in melanoma metastases and associated to resistance to oxidative stress-induced apoptosis",
  151. (1998). Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins",
  152. (2006). Distinct subcellular localization for constitutive and agonist-modulated palmitoylation of the human delta opioid receptor",
  153. (2005). Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes",
  154. (1995). Distribution of betaamyloid protein in the brain following severe head injury", Neuropathology and applied neurobiology,
  155. (2003). Dutch, Flemish, Italian, and Arctic mutations of APP and resistance of Abeta to physiologically relevant proteolytic degradation",
  156. (2009). Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve", Brain : a journal of neurology,
  157. (1997). Ectodomain phosphorylation of beta-amyloid precursor protein at two distinct cellular locations",
  158. (2004). Effect of hypoxia/ischemia and hypoxic preconditioning/reperfusion on expression of some amyloid-degrading enzymes",
  159. (2001). Effects of closed traumatic brain injury and genetic factors on the development of Alzheimer's disease",
  160. (2000). Effects of the beta-Amyloid Peptide on Membrane Ion Permeability",
  161. (2000). Effects-of fluoxetine on sensorimotor and spatial learning deficits following focal cerebral ischemia in rats",
  162. (2006). Elevated cerebrospinal fluid pressure in patients with Alzheimer's disease",
  163. (2008). Emerging views of corticothalamic function",
  164. (2004). Endoplasmic reticulumlocalized amyloid beta-peptide is degraded in the cytosol by two distinct degradation pathways", Traffic
  165. (2009). Enhanced generation of Alzheimer's amyloid-beta following chronic exposure to phorbol ester correlates with differential effects on alpha and epsilon isozymes of protein kinase C",
  166. (2003). Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death",
  167. (2005). Evaluation of cholinergic markers in Alzheimer's disease and in a model of cholinergic deficit",
  168. (1997). Evidence that levels of presenilins (PS1 and PS2) are coordinately regulated by competition for limiting cellular factors",
  169. (1994). Evidence that production and release of amyloid betaprotein involves the endocytic pathway",
  170. (1996). Experimental brain injury induces differential expression of tumor necrosis factoralpha mRNA in the CNS", Brain research.Molecular brain research,
  171. (2004). Experimental traumatic brain injury in rats stimulates the expression,82 production and activity of Alzheimer's disease beta-secretase (BACE-1)", Journal of neural transmission
  172. (2000). Export from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human delta opioid receptor",
  173. (2000). Expression analysis of BACE2 in brain and peripheral tissues",
  174. (1994). Expression of a ubiquitous, cross-reactive homologue of the mouse beta-amyloid precursor protein (APP)",
  175. (1996). Expression of beta-amyloid precursor protein mRNAs following transient focal ischaemia",
  176. (2005). Expression of the antiapoptotic gene seladin-1 and octreotide-induced apoptosis in growth hormone-secreting and nonfunctioning pituitary adenomas",
  177. (1995). Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene",
  178. (1996). Familial Alzheimer's diseaselinked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo",
  179. (2009). Flanking markers of cystatin c (CST3) gene do not show association with Alzheimer's disease", Dementia and geriatric cognitive disorders,
  180. (2003). Forelimb use after focal cerebral ischemia in rats treated with an alpha 2-adrenoceptor antagonist",
  181. (1999). Function and dysfunction of the presenilins",
  182. (2009). Functional roles of amyloid-beta protein precursor and amyloid-beta peptides: evidence from experimental studies",
  183. (2009). gamma-Secretase: successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment",
  184. (2005). Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease",
  185. (1995). Generation of amyloid beta protein from its precursor is sequence specific",
  186. (1997). Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population",
  187. (2008). Genetic study evaluating LDLR polymorphisms and Alzheimer's disease",
  188. (2007). Genetics of Alzheimer's disease: a centennial review",
  189. (1998). Genetics of Alzheimer's disease",
  190. (2009). Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease",
  191. (2009). Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease",
  192. (1991). Genomic organization of the human-amyloid beta-protein precursor gene",
  193. (2004). GGA proteins bind ubiquitin to facilitate sorting at the trans-Golgi network",
  194. (2005). GGA proteins mediate the recycling pathway of memapsin 2 (BACE)",
  195. (2001). Global assessment measures in dementia"
  196. (1996). Glycoprotein 330/megalin: probable role in receptormediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers",
  197. (2001). Heritability of plasma amyloid beta in typical late-onset Alzheimer's disease pedigrees",
  198. (1993). Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease",
  199. (2010). High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters",
  200. (2000). Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein",
  201. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade",
  202. (1999). Identification of a novel aspartic protease (Asp 2) as beta-secretase", Molecular and cellular neurosciences,
  203. (1989). Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein",
  204. (2000). Identifying proteases that cleave APP",
  205. (2004). Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B",
  206. (2008). Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism",
  207. (1996). Increased activity-regulating and neuroprotective efficacy of alphasecretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain",
  208. (1993). Increased amyloid betapeptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease",
  209. (2004). Increased beta-secretase activity and expression in rats following transient cerebral ischemia",
  210. (1998). Insulin degradation: progress and potential",
  211. (2000). Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinasedependent pathway", The FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
  212. (2003). Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo",
  213. (2005). Interactions between Alzheimer's disease and cerebral ischemia--focus on inflammation",
  214. (2004). Interactions of GGA3 with the ubiquitin sorting machinery",
  215. (2007). Intracellular amyloid-beta in Alzheimer's disease",
  216. (2002). Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology", The American journal of pathology,
  217. (2004). Intraneuronal amyloid-beta1-42 production triggered by sustained increase of cytosolic calcium concentration induces neuronal death",
  218. (2006). Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans",
  219. (2009). K63-linked ubiquitin chains as a specific signal for protein sorting into the multivesicular body pathway",
  220. (2008). Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis",
  221. (2005). Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclindependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease",
  222. (2005). Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase",
  223. (2010). Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB",
  224. (2006). Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment",
  225. (2003). LRP: a bright beacon at the blood-brain barrier",
  226. (2004). LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms",
  227. (2006). Luteinizing hormone receptor ectodomain splice variant misroutes the full-length receptor into a subcompartment of the endoplasmic reticulum", Molecular biology of the cell,
  228. (1998). Mechanisms of calcium and sodium fluxes in anoxic myelinated central nervous system axons",
  229. (2009). Mechanisms of tau-induced neurodegeneration",
  230. (1999). Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity",
  231. (1999). Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor protein",
  232. (1996). Metabolism of Alzheimer betaamyloid precursor protein: regulation by protein kinase A in intact cells and in a cellfree system",
  233. (2006). Micro-blood-brain barrier openings and cytotoxic fragments of amyloid precursor protein accumulation in white matter after ischemic brain injury in long-lived rats",
  234. (2004). Mild cognitive impairment as a diagnostic entity",
  235. (1975). Mini-mental state". A practical method for grading the cognitive state of patients for the clinician",
  236. (1999). Mitochondria, NO and neurodegeneration",
  237. (2006). Mitochondrial dysfunction in sporadic and genetic Alzheimer's disease",
  238. (2000). Molecular mechanism of neurodegeneration induced by Alzheimer's beta-amyloid protein: channel formation and disruption of calcium homeostasis",
  239. (2008). MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study",
  240. (2001). Mu-, delta- and kappa-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer's disease patients",
  241. (2010). Muistioireiden ja dementian epidemiologia."
  242. (2007). Multicenter assessment of CSFphosphorylated tau for the prediction of conversion of MCI",
  243. (2010). Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer's disease",
  244. (2001). Mutations in the 3betahydroxysterol Delta24-reductase gene cause desmosterolosis, an autosomal recessive disorder of cholesterol biosynthesis",
  245. (2002). N -Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth",
  246. (2008). N-glycan-mediated quality control in the endoplasmic reticulum is required for the expression of correctly folded delta-opioid receptors at the cell surface",
  247. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo",
  248. (2010). Nature versus nurture: death of a dogma, and the road ahead",
  249. (2004). Necrosis, apoptosis and hybrid death in the cortex and thalamus after barrel cortex ischemia in rats",
  250. (2009). Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease",
  251. (2003). Neprilysin gene transfer reduces human amyloid pathology in transgenic mice",
  252. (2010). Nerve growth factor-regulated emergence of functional delta-opioid receptors",
  253. (1990). Neural damage in the rat thalamus after cortical infarcts", Stroke; a journal of cerebral circulation,
  254. (1999). Neurite-outgrowth regulating functions of the amyloid protein precursor of Alzheimer's disease",
  255. (1998). Neurofibrillary degeneration and cell loss in the nucleus basalis in comparison to cortical Alzheimer pathology",
  256. (2004). Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice",
  257. (2004). Neuronal membrane cholesterol loss enhances amyloid peptide generation",
  258. (1985). Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels",
  259. (2003). Neuropathologic changes in Alzheimer's disease",
  260. (1991). Neuropathological stageing of Alzheimer-related changes",
  261. (2003). Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity",
  262. (2008). Neuropsychological contributions to the early identification of Alzheimer's disease",
  263. (2003). Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease",
  264. (2010). New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population", Dementia and geriatric cognitive disorders,
  265. (2008). No association between CALHM1 and Alzheimer's disease risk",
  266. (2008). Novel role of CXCR2 in regulation of gamma-secretase activity",
  267. (2004). Novel ventriculoperitoneal shunt in Alzheimer's disease cerebrospinal fluid biomarkers", Expert review of neurotherapeutics,
  268. (2009). Nuclear signaling by the APP intracellular domain occurs predominantly through the amyloidogenic processing pathway",
  269. (2007). Opioid receptor pharmacological chaperones act by binding and stabilizing newly synthesized receptors in the endoplasmic reticulum",
  270. (2004). Opioid receptors",
  271. (2010). Opioid-receptor-heteromer-specific trafficking and pharmacology", Current opinion in pharmacology,
  272. (2005). Oxidative stress potentiates BACE1 gene expression and Abeta generation",
  273. (2005). P2Y2 nucleotide receptors enhance alpha-secretase-dependent amyloid precursor protein processing",
  274. (2003). Partial purification and characterization of gamma-secretase from post-mortem human brain",
  275. (2002). Perinnöllisyys ja geenitestit" in Muistihäiriöt ja dementia,
  276. (2004). PET imaging of amyloid in Alzheimer's disease",
  277. (1989). pH-dependent effects of bepridil on Ca2+-extrusion across rat heart sarcolemma",
  278. (2009). Phe27Cys polymorphism alters the maturation and subcellular localization of the human delta opioid receptor", Traffic
  279. (2008). Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis",
  280. (2001). Phosphorylation regulates intracellular trafficking of beta-secretase",
  281. (1991). Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment",
  282. (2001). Post-translational processing of betasecretase (beta-amyloid-converting enzyme) and its ectodomain shedding. The pro- and transmembrane/cytosolic domains affect its cellular activity and amyloid-beta production",
  283. (2011). Potent amyloidogenicity and pathogenicity of Abeta43",
  284. (1989). Predisposing locus for Alzheimer's disease on chromosome 21",
  285. (2007). Presenilin: running with scissors in the membrane",
  286. (2005). Presenilin/gamma-secretase-mediated cleavage of the voltage-gated sodium channel beta2-subunit regulates cell adhesion and migration",
  287. (1991). Processing of beta-amyloid precursor protein in microglia and astrocytes favors an internal localization over constitutive secretion",
  288. (1992). Processing of the amyloid protein precursor to potentially amyloidogenic derivatives",
  289. (1999). Progressive parenchymal deposition of beta-amyloid precursor protein in rat brain following global cerebral ischemia",
  290. (2008). Prosurvival effect of DHCR24/Seladin-1 in acute and chronic responses to oxidative stress", Molecular and cellular biology,
  291. (1988). Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer's disease",
  292. (1993). Protein phosphorylation inhibits production of Alzheimer amyloid beta/A4 peptide",
  293. (1992). Protein phosphorylation regulates secretion of Alzheimer beta/A4 amyloid precursor protein",
  294. (2000). Proteolytic processing and cell biological functions of the amyloid precursor protein",
  295. (1999). Purification and cloning of amyloid precursor protein beta-secretase from human brain",
  296. (2002). Rab proteins mediate Golgi transport of caveola-internalized glycosphingolipids and correct lipid trafficking in Niemann-Pick C cells",
  297. (2003). RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain",
  298. (2002). Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis",
  299. (2000). Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis",
  300. (2007). Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline",
  301. (1997). Regulation of amyloid precursor protein catabolism involves the mitogenactivated protein kinase signal transduction pathway",
  302. (2004). Regulation of cellular response to oncogenic and oxidative stress by Seladin-1",
  303. (2009). Relationships between biomarkers in aging and dementia",
  304. (1992). Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors",
  305. (2007). Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria",
  306. (1989). Reversible middle cerebral artery occlusion without craniectomy in rats", Stroke; a journal of cerebral circulation,
  307. (2010). Revising the definition of Alzheimer's disease: a new lexicon",
  308. (1994). Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease",
  309. (2006). Role of genes and environments for explaining Alzheimer disease",
  310. (2003). Role of protein kinase C alpha in the regulated secretion of the amyloid precursor protein",
  311. (2001). Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's type", Brain research.Brain research reviews,
  312. (1996). Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease",
  313. (1997). Secreted form of beta-amyloid precursor protein shifts the frequency dependency for induction of LTD, and enhances LTP in hippocampal slices",
  314. (2002). Seladin-1 transcription is linked to neuronal degeneration in Alzheimer's disease",
  315. (1991). Selective induction of Kunitz-type protease inhibitor domain-containing amyloid precursor protein mRNA after persistent focal ischemia in rat cerebral cortex",
  316. (1983). Senile dementia of the Alzheimer type",
  317. (2007). Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study",
  318. (1999). Shunting effects in patients with idiopathic normal pressure hydrocephalus; correlation with cerebral and leptomeningeal biopsy findings",
  319. (2011). Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration",
  320. (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide", Nature reviews.Molecular cell biology,
  321. (2006). Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis",
  322. (2005). Spatial segregation of gamma-secretase and substrates in distinct membrane domains",
  323. (2004). Strategies for disease modification in Alzheimer's disease",
  324. (2003). Stroke and the risk of Alzheimer disease",
  325. (1999). Structural Neuroimaging: Early Diagnosis and Staging of Alzheimer's disease"
  326. (2004). Subcellular topography of neuronal Abeta peptide in APPxPS1 transgenic mice", The American journal of pathology,
  327. (2007). Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptide-induced dysfunction",
  328. (1997). Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease", Human molecular genetics,
  329. (2007). Systematic metaanalyses of Alzheimer disease genetic association studies: the AlzGene database",
  330. (2009). Systemic inflammation and disease progression in Alzheimer disease",
  331. (2002). Tau is essential to beta -amyloid-induced neurotoxicity",
  332. (2005). Tau pathology in Alzheimer disease and other tauopathies",
  333. (2000). Tau protein isoforms, phosphorylation and role in neurodegenerative disorders", Brain research.Brain research reviews,
  334. (2010). Tau reduction prevents Abeta-induced defects in axonal transport",
  335. (2007). Tauopathies", Cellular and molecular life sciences : CMLS,
  336. (1990). Thalamic retrograde degeneration following cortical injury: an excitotoxic process?",
  337. (1993). The Alzheimer beta-amyloid protein precursor/protease nexin-II is cleaved by secretase in a trans-Golgi secretory compartment in human neuroglioma cells",
  338. (2007). The Alzheimer's disease beta-secretase enzyme, BACE1",
  339. (2006). The amyloid precursor protein: beyond amyloid",
  340. (2004). The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor",
  341. (2007). The association study between DHCR24 polymorphisms and Alzheimer's disease",
  342. (2001). The BACE gene: genomic structure and candidate gene study in late-onset Alzheimer's disease",
  343. (2009). The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential",
  344. (2004). The biogenesis of multivesicular endosomes", Nature reviews.Molecular cell biology,
  345. (1993). The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease",
  346. (2003). The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1",
  347. (1982). The cholinergic hypothesis of geriatric memory dysfunction",
  348. (1998). The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease",
  349. (1993). The Clinical Dementia Rating (CDR): current version and scoring rules",
  350. (1991). The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease",
  351. (2010). The dysregulation of intracellular calcium in Alzheimer disease",
  352. (1996). The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology",
  353. (2007). The endoplasmic reticulum Ca2+-pump SERCA2b interacts with G protein-coupled receptors and enhances their expression at the cell surface",
  354. (2004). The gamma-secretase complex: machinery for intramembrane proteolysis", Current opinion in neurobiology,
  355. (1987). The genetic defect causing familial Alzheimer's disease maps on chromosome 21", Science
  356. (2010). The genetics of Alzheimer disease: back to the future",
  357. (2004). The GGA proteins: adaptors on the move", Nature reviews.Molecular cell biology,
  358. (1982). The Global Deterioration Scale for assessment of primary degenerative dementia",
  359. (2000). The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress",
  360. (2011). The Many Substrates of Presenilin/gamma-Secretase",
  361. (2001). The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function", BioEssays : news and reviews in molecular, cellular and developmental biology,
  362. (2008). The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk",
  363. (2009). The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons",
  364. (1987). The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor",
  365. (1998). The role of A beta 42 in Alzheimer's disease",
  366. (2011). The role of G protein-coupled receptors in the pathology of Alzheimer's disease",
  367. (2006). The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo",
  368. (2009). The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha",
  369. (2010). The use of PET in Alzheimer disease",
  370. (2008). Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses",
  371. (1989). Tissue-specific expression of three types of beta-protein precursor mRNA: enhancement of protease inhibitor-harboring types in Alzheimer's disease brain", Biochemical and biophysical research communications,
  372. (2005). Transformation of diffuse beta-amyloid precursor protein and beta-amyloid deposits to plaques in the thalamus after transient occlusion of the middle cerebral artery in rats", Stroke; a journal of cerebral circulation,
  373. (1985). Transmitter deficits in Alzheimer's disease",
  374. (2008). Transthyretin protects against A-beta peptide toxicity by proteolytic cleavage of the peptide: a mechanism sensitive to the Kunitz protease inhibitor",
  375. (2008). Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Abeta toxicity",
  376. (1994). Transthyretin sequesters amyloid beta protein and prevents amyloid formation",
  377. (2000). Traumatic brain injury elevates the Alzheimer's amyloid peptide A beta 42 in human CSF. A possible role for nerve cell injury",
  378. (2005). Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective",
  379. (2001). Typical clinical features" in Clinical diagnosis and management of Alzheimer's disese, 2. revised edn,
  380. (2006). Ubiquilin 1 modulates amyloid precursor protein trafficking and Abeta secretion",
  381. (2010). Ubiquitin regulates GGA3-mediated degradation of BACE1",
  382. (2002). Vascular disorder in Alzheimer's disease: role in pathogenesis of dementia and therapeutic targets",

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.